Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

Autor: Daniel Weghuber, Klaus Boberg, Dan Hesse, Ole K Jeppesen, Rasmus Sørrig, Aaron S Kelly

Publikováno v: Journal of Comparative Effectiveness Research, Vol 12, Iss 2 (2022)

What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the New England Journal of Medicine. As more teenagers are living with obesity than ever before, researchers are search

Externí odkaz: https://doaj.org/article/21453729b1da451ebf2c22657495a211

Treatment With Once-weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity and Type 2 Diabetes: STEP 2 Post Hoc Analysis

Autor: David Lau, John E Deanfield, Melanie Davies, Timothy W Garvey, Ole K Jeppesen, Usman Khalid, Mikhail Kosiborod, Robert F Kushner, Peter N Laursen, Domenica M Rubino, Subodh Verma

Publikováno v: Canadian Journal of Diabetes. 46:S27-S28

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::58e416d42d8a4c521d417bd173a45bab
https://doi.org/10.1016/j.jcjd.2022.09.079

3 Efficacy and Safety of Semaglutide 2.4 mg Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)

Autor: Iichiro Shimomura, Ole K. Jeppesen, Adie Viljoen, Louise Færch, Arash Pakseresht, Ildiko Lingvay, Sue D. Pedersen, Leigh Perreault, Melanie J. Davies, René Gollan, Julio Rosenstock, Thomas A. Wadden

Publikováno v: Adipositas-Kongress 2021 – 37. Jahrestagung der Deutschen Adipositas-Gesellschaft e.V..

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f573cc71b5ce8f12da85da3d6c95853f
https://doi.org/10.1055/s-0041-1735690

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Autor: Ole K. Jeppesen, Louise Færch, Thomas A. Wadden, Adie Viljoen, Melanie J. Davies, Julio Rosenstock, Ildiko Lingvay, Arash Pakseresht, Leigh Perreault, Iichiro Shimomura, Sue D. Pedersen

Publikováno v: Lancet (London, England). 397(10278)

Summary Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea13642496cae902a71ce7170cbbf2e4
https://pubmed.ncbi.nlm.nih.gov/33667415

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Autor: Pankaj Joshi, Michael A. Nauck, Mansoor Husain, Mette Thomsen, Abdurrahman Comlekci, Ofri Mosenzon, Denise R. Franco, Kathleen Dungan, Wayne Huey-Herng Sheu, Mette Strange, Jeppe Gram, Nikhil Tandon, Stephen C. Bain, Maria C. Faingold, Cees J. Tack, Cristian Guja, Ole K. Jeppesen, Chaicharn Deerochanawong, Robert Silver, Agostino Consoli, Michael E. Farkouh, Rosario Arechavaleta, Sue D. Pedersen, Paweł Bogdański, Rachid Malek, Juan F. Merino-Torres

Publikováno v: Diabetes, Obesity & Metabolism
Bain, S C, Mosenzon, O, Arechavaleta, R, Bogdański, P, Comlekci, A, Consoli, A, Deerochanawong, C, Dungan, K, Faingold, M C, Farkouh, M E, Franco, D R, Gram, J, Guja, C, Joshi, P, Malek, R, Merino-Torres, J F, Nauck, M A, Pedersen, S D, Sheu, W H H, Silver, R J, Tack, C J, Tandon, N, Jeppesen, O K, Strange, M, Thomsen, M & Husain, M 2019, ' Cardiovascular safety of oral semaglutide in patients with type 2 diabetes : Rationale, design and patient baseline characteristics for the PIONEER 6 trial ', Diabetes, Obesity and Metabolism, vol. 21, no. 3, pp. 499-508 . https://doi.org/10.1111/dom.13553
Diabetes, Obesity & Metabolism, 21, 499-508
DIABETES OBESITY & METABOLISM
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Diabetes, Obesity & Metabolism, 21, 3, pp. 499-508

Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agonist. Materials and methods: PIONEER 6 is a multinational, randomized, placebo-controlled, double-blind trial in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54341ae6292c251c8c3acbf8d25f23d5
https://doi.org/10.1111/dom.13553